Literature DB >> 6298119

Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome.

S Harada, T Bechtold, J K Seeley, D T Purtilo.   

Abstract

The activity of T-cell-mediated immunity to Epstein-Barr virus (EBV) was assessed by an assay of regression of the outgrowth of EBV-infected autologous B cells. Regression and natural killer (NK)-cell activities were compared for patients and their mothers from five families with X-linked lymphoproliferative syndrome (XLP) and three control groups. Seven of the 10 patients with XLP exhibited weak T-cell activity against autologous EBV-infected lymphoblastoid cell lines (LCL) comparable to EBV-seronegative controls. In contrast, 8 of 10 obligate carrier females of XLP had unusually strong activity, which was comparable to anti-early-antigen (EA) positive controls. The results of the regression assays correlated with their EBV serology: mothers showed high titers, and their affected sons showed low-titer EBV-specific antibody responses. Defective NK-cell activity was found only in the patients with XLP. NK and regression activities did not correlate. Our findings explain, in part, the vulnerability to EBV of males with XLP and why their mothers are protected from life-threatening phenotypes of XLP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298119     DOI: 10.1002/ijc.2910300610

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Epstein-Barr virus specific antibodies in patients with coeliac disease.

Authors:  S Harada; J Greally; J Davis; N Synder; F Stevens; C McCarthy; D T Purtilo
Journal:  Ir J Med Sci       Date:  1985-11       Impact factor: 1.568

2.  Stress, loneliness, and changes in herpesvirus latency.

Authors:  R Glaser; J K Kiecolt-Glaser; C E Speicher; J E Holliday
Journal:  J Behav Med       Date:  1985-09

3.  A family study of the X-linked lymphoproliferative syndrome: evidence for a B cell defect contributing to the immunodeficiency.

Authors:  I Ando; G Morgan; R J Levinsky; D H Crawford
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

Review 4.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity.

Authors:  F Rousset; G Souillet; M G Roncarolo; J P Lamelin
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

Review 6.  NK cells, innate immunity and hepatitis C infection after liver transplantation.

Authors:  Anoma Nellore; Jay A Fishman
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

7.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

Review 8.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

9.  Oncological consequences of impaired immune surveillance against ubiquitous viruses.

Authors:  D T Purtilo; J Linder
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

Review 10.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.